Skip to content
Snippets Groups Projects
Commit 443f4a3d authored by Isabell Alexandra Guckes's avatar Isabell Alexandra Guckes
Browse files

Update file drug-data.tsx

parent de08ff02
No related branches found
No related tags found
No related merge requests found
Pipeline #444045 passed with warnings
......@@ -56,7 +56,7 @@ export const drugdata: (Array<DrugDatensatz>) = [
{
name: "Mucolytics and inhalation", //gibt 2 Inhalation Beispiele
picture: "...",
introduction: "Mucolytics help thin and loosen the mucus in the lungs, making it easier to cough up and clear the airways. These therapies are typically administered via wet or dry inhalation, providing direct delivery to the lungs. In the case of wet inhalation, the medication is inhaled as an aqueous solution and nebulised, while in the case of dry inhalation, the medication is inhaled as a powder. [1] Key Therapies include mannitol, Pulmozyme® and hypertonic saline.",
introduction: "Mucolytics help thin and loosen the mucus in the lungs, making it easier to cough up and clear the airways. These therapies are typically administered via wet or dry inhalation, providing direct delivery to the lungs. In the case of wet inhalation, the medication is inhaled as an aqueous solution and nebulized, while in the case of dry inhalation, the medication is inhaled as a powder. [1] Key Therapies include mannitol, Pulmozyme® and hypertonic saline.",
examples: [
{
title: "Pulmozyme", //quelle 8
......@@ -75,7 +75,7 @@ export const drugdata: (Array<DrugDatensatz>) = [
examples: [
{
title: "TOBI", //quelle 13 + Pseudo muss kursiv
text: ["Active ingredient(s): Tobramycin",<>Indications: For CF patients aged 6 years and older with <i> Pseudomonas aeruginosa </i> infections </>,"Mechanism: Aminoglycoside antibiotic disrupts bacterial protein synthesis, leading to the death of the pathogen","Administration: Inhalation of antibiotic via nebuliser, typically taken twice daily in 28-day cycles","Approval: Approved by the EMA in 2011 [14]"]
text: ["Active ingredient(s): Tobramycin",<>Indications: For CF patients aged 6 years and older with <i> Pseudomonas aeruginosa </i> infections </>,"Mechanism: Aminoglycoside antibiotic disrupts bacterial protein synthesis, leading to the death of the pathogen","Administration: Inhalation of antibiotic via nebulizer, typically taken twice daily in 28-day cycles","Approval: Approved by the EMA in 2011 [14]"]
},
{
title: "CAYSTON", //quelle 15 + Pseudo muss kursiv
......
0% Loading or .
You are about to add 0 people to the discussion. Proceed with caution.
Finish editing this message first!
Please register or to comment